EU-ROS’ WGs are strongly linked and integrated. Indeed, the objectives of each WG can only be achieved through continuous exchange of information and materials. Therefore, WG6 enables optimal transfer (e.g. by staff exchange and Training Schools) and joint use by participating groups to the benefit of all EU-ROS members. EU-ROS will for example organise multi-centre, pre-clinical studies to test drug candidates and validate animal models at different member labs. This will increase the likelihood of successful translation into the clinics and reduce the costs of drop out. Indeed, nowadays too many drug candidates fail in clinical developments, and this is – amongst obvious reasons e.g. inherited differences between human and animals – caused by insufficient quality of preclinical research. WG6 therefore implements and control quality issues for its scientific activities, such as SOPs.